Antiplatelets

A landmark analysis from the NEOMINDSET trial demonstrates that while potent P2Y12 inhibitor monotherapy reduces bleeding, it significantly increases ischemic risk in the first 30 days after PCI for acute coronary syndrome, suggesting that the timing of aspirin withdrawal is critical for patient safety.